Overview
Legal name
XENTION LIMITED
Region
East of England
Registered address
Unknown
Insolvency history
No
Company
Active
LTD
Company profile
Xention Limited
Xention Limited is a UK company with status active founded in 2002 based in East of England.
CRN
04452808
Founded
2002
Age
23
Corporate ownership
Updated 06 Jun 2026 16:52
1 level
1 ultimate controller
1
Company
Active
LTD
Xention Limited
CRN 04452808
2
Direct and ultimate controller
Active
LTD
Xention Pharma Limited
CRN 07376729
Company events
Reference milestones and recent Companies House filing stream events.
3 events
07 Apr
2026
Gazette Dissolved Voluntary
GazetteGAZ2(A) | Transaction MzUxMzcyMTYzOWFkaXF6a2N4 | Paper/PDF filed
Published 03 Apr 2026 23:20
30 Sep
2024
Accounts With Accounts Type Total Exemption Full
Accounts PDF pendingAA | Transaction MzQzNzIyMTYyOGFkaXF6a2N4 | Paper/PDF filed
Published 02 Oct 2024 06:19
31 May
2002
Incorporated
InceptionCompany registered at Companies House
Public funding
4 awards
First funded
2010
Funded years
2010, 2013, 2014
Age at first award
8 years
Projects
2014
Feasibility Studies
Lead participant
Development of a translational model system of the spinal pain synapse
1 Jul 2014 to 30 Jun 2015
Awarded
£144,795
Total cost £193,060
The discovery of new drugs has become an extremely costly and time-consuming activity, and is associated with many late-stage failures. After 30 years of research there still remains a large unmet need for safe and effective treatments for chornic pain. One of the reasons for so many clinical failures, especially in the area of pain drug discovery, is the...
2014
Collaborative R&D
Lead participant
Development of a novel IKACh inhibitor for the treatment of atrial fibrillation
1 May 2014 to 31 Aug 2016
Awarded
£1,139,510
Total cost £1,899,185
Awaiting
2013
Feasibility Studies
Lead participant
TRPA1 hit expansion and validation
1 Mar 2013 to 30 Apr 2014
Awarded
£143,909
Total cost £191,930
Respiratory diseases, such as asthma and chronic obstructive pulmonary disease (COPD), are increasing within the global population. The UK has the highest prevalence of asthma in the world, with ~9 million people of all ages and race affected and where 90% of deaths are preventable. 3.2 Million people have COPD and ~23,000 people die from the disease each...
2010
EU-Funded
Lead participant
ICRAC
1 Jun 2010 to 30 Jun 2013
Awarded
£311,116
Total cost £622,202
Awaiting Public Project Summary
Product types
Collaborative R&D
EU-Funded
Feasibility Studies